Christine Dierks

Summary

Affiliation: University Hospital
Country: Germany

Publications

  1. doi request reprint GDC-0449--targeting the hedgehog signaling pathway
    Christine Dierks
    Department of Hematology and Oncology, Freiburg University Medical Center, Hugstetterstrasse 55, 79106, Freiburg, Germany
    Recent Results Cancer Res 184:235-8. 2010
  2. doi request reprint Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation
    Christine Dierks
    Department of Hematology Oncology, University of Freiburg, Hugstetter Strasse 55, 79106 Freiburg, Germany
    Cancer Cell 14:238-49. 2008
  3. doi request reprint The ITK-SYK fusion oncogene induces a T-cell lymphoproliferative disease in mice mimicking human disease
    Christine Dierks
    Hematology Oncology, University of Freiburg, Freiburg, Germany
    Cancer Res 70:6193-204. 2010
  4. doi request reprint Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia
    Maike Buchner
    Department of Hematology and Oncology, University Medical Center Freiburg, Freiburg, Germany
    Blood 115:4497-506. 2010
  5. doi request reprint Insulin-like growth factor-1 receptor (IGF1R) as a novel target in chronic lymphocytic leukemia
    Niuscha Yaktapour
    Department of Hematology Oncology, University Medical Center Freiburg, Freiburg, Germany
    Blood 122:1621-33. 2013
  6. doi request reprint Trisomy 12 and elevated GLI1 and PTCH1 transcript levels are biomarkers for Hedgehog-inhibitor responsiveness in CLL
    Sarah Decker
    Department of Hematology Oncology, University Medical Center Freiburg, Hugstetter Strasse 55, Freiburg, Germany
    Blood 119:997-1007. 2012
  7. pmc Ptch2 loss drives myeloproliferation and myeloproliferative neoplasm progression
    Claudius Klein
    Department of Hematology Oncology, University Medical Center Freiburg, D 79106 Freiburg, Germany Institute for Molecular Medicine and Cell Research, University of Freiburg, D 79104 Freiburg, Germany
    J Exp Med 213:273-90. 2016
  8. doi request reprint The microenvironment differentially impairs passive and active immunotherapy in chronic lymphocytic leukaemia - CXCR4 antagonists as potential adjuvants for monoclonal antibodies
    Maike Buchner
    Department of Haematology and Oncology, University Medical Centre Freiburg, Freiburg, Germany
    Br J Haematol 151:167-78. 2010
  9. pmc Spleen Tyrosine Kinase Is Involved in the CD38 Signal Transduction Pathway in Chronic Lymphocytic Leukemia
    Marco Benkisser-Petersen
    Department of Hematology, Oncology and Stem Cell Transplantation, University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany
    PLoS ONE 11:e0169159. 2016
  10. doi request reprint Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia
    Maike Buchner
    University Medical Center Freiburg, Department of Hematology and Oncology, Germany
    Cancer Res 69:5424-32. 2009

Collaborators

  • Stephan Stilgenbauer
  • Hendrik Veelken
  • Meike Burger
  • Konrad Aumann
  • Markus Warmuth
  • H Jumaa
  • John Gribben
  • Fabio Malavasi
  • Michael Reth
  • Rainer Claus
  • Juerg Schwaller
  • Hermann Eibel
  • Gorica Nikoloski
  • Thorsten Zenz
  • Hong Ma
  • Robert A J Oostendorp
  • Katja Zirlik
  • Maike Buchner
  • Sarah Decker
  • Dietmar Pfeifer
  • Gabriele Prinz
  • Marco Benkisser-Petersen
  • Justus Duyster
  • Claudius Klein
  • Marie Follo
  • Sandra Kissel
  • Jonas S Jutzi
  • Niuscha Yaktapour
  • HEIKE PAHL
  • Marcus Dühren-von-Minden
  • Thomas Benkler
  • Arlette Dörffel
  • Christine Ulrike Forster
  • Anna Lena Illert
  • Kathrin Kläsener
  • Anabel Zwick
  • Kerstin Leberecht
  • Nathanael Gray
  • Anabel Kuhn
  • Thomas Sebastian Mack
  • Aaron James Forde
  • Chandrasekhar V Miduturu
  • Johannes Finter
  • Ruzhica Bogeska
  • Jan C Peeken
  • Thalia S Seeger
  • Julius Wehrle
  • Joop H Jansen
  • Albert Gründer
  • Rudolf Ubelhart
  • Tilman Brummer
  • Wei Kamar Wang
  • Heike L Pahl
  • Kamar Hamdi
  • Sven Schwemmers
  • Corina A Schmid
  • Frank Stegelmann
  • Julia Schuler
  • Konstanze Dohner
  • Monika Gothwal
  • Annette Schmitt-Graeff
  • David Hartmann
  • Dieter Herchenbach
  • Lauritte Djebatchie
  • Gabriele Ihorst
  • Ariane Ott
  • Constance Bär
  • Philipp Brantner
  • Constance Baer
  • Roland Mertelsmann
  • Natalie Stickel
  • Kilian Bartholomé
  • Simon Fuchs
  • Jens Timmer
  • Laurent Vallat
  • Nina Chevalier

Detail Information

Publications12

  1. doi request reprint GDC-0449--targeting the hedgehog signaling pathway
    Christine Dierks
    Department of Hematology and Oncology, Freiburg University Medical Center, Hugstetterstrasse 55, 79106, Freiburg, Germany
    Recent Results Cancer Res 184:235-8. 2010
    ..It was successfully tested in a phase-I clinical trial demonstrating good pharmacodynamic (PD) and pharmacokinetic (PK) properties and showing objective response and clinical benefit in several patients with basal cell carcinoma...
  2. doi request reprint Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation
    Christine Dierks
    Department of Hematology Oncology, University of Freiburg, Hugstetter Strasse 55, 79106 Freiburg, Germany
    Cancer Cell 14:238-49. 2008
    ..Pharmacological Smo inhibition reduced LSCs in vivo and enhanced time to relapse after end of treatment. Our results indicate that Smo inhibition might be an effective treatment strategy to reduce the LSC pool in CML...
  3. doi request reprint The ITK-SYK fusion oncogene induces a T-cell lymphoproliferative disease in mice mimicking human disease
    Christine Dierks
    Hematology Oncology, University of Freiburg, Freiburg, Germany
    Cancer Res 70:6193-204. 2010
    ..Therefore, pharmacologic inhibition of SYK in patients with U-PTCLs carrying the ITK-SYK fusion protein might be an effective treatment strategy...
  4. doi request reprint Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia
    Maike Buchner
    Department of Hematology and Oncology, University Medical Center Freiburg, Freiburg, Germany
    Blood 115:4497-506. 2010
    ..SYK blockade in CLL is a promising therapeutic principle not only for its inhibition of the BCR signaling pathway, but also by inhibiting protective stroma signals in a manner entirely independent of BCR signaling...
  5. doi request reprint Insulin-like growth factor-1 receptor (IGF1R) as a novel target in chronic lymphocytic leukemia
    Niuscha Yaktapour
    Department of Hematology Oncology, University Medical Center Freiburg, Freiburg, Germany
    Blood 122:1621-33. 2013
    ..Importantly, IGF1R inhibitors compromise CLL viability in their microenvironment context, implicating this RTK as a promising therapeutic target. ..
  6. doi request reprint Trisomy 12 and elevated GLI1 and PTCH1 transcript levels are biomarkers for Hedgehog-inhibitor responsiveness in CLL
    Sarah Decker
    Department of Hematology Oncology, University Medical Center Freiburg, Hugstetter Strasse 55, Freiburg, Germany
    Blood 119:997-1007. 2012
    ....
  7. pmc Ptch2 loss drives myeloproliferation and myeloproliferative neoplasm progression
    Claudius Klein
    Department of Hematology Oncology, University Medical Center Freiburg, D 79106 Freiburg, Germany Institute for Molecular Medicine and Cell Research, University of Freiburg, D 79104 Freiburg, Germany
    J Exp Med 213:273-90. 2016
    ..Our findings suggest HH ligand inhibitors as possible drug candidates that act on hematopoiesis and the niche to prevent transformation of MPNs into leukemias. ..
  8. doi request reprint The microenvironment differentially impairs passive and active immunotherapy in chronic lymphocytic leukaemia - CXCR4 antagonists as potential adjuvants for monoclonal antibodies
    Maike Buchner
    Department of Haematology and Oncology, University Medical Centre Freiburg, Freiburg, Germany
    Br J Haematol 151:167-78. 2010
    ..Our data identify the combination of CXCR4 antagonists with passive - but not active - immunotherapy as a promising potential treatment concept in CLL...
  9. pmc Spleen Tyrosine Kinase Is Involved in the CD38 Signal Transduction Pathway in Chronic Lymphocytic Leukemia
    Marco Benkisser-Petersen
    Department of Hematology, Oncology and Stem Cell Transplantation, University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany
    PLoS ONE 11:e0169159. 2016
    ..Finally, we observed a clear correlation between CD38 expression on CLL cells and SYK-inhibitor efficacy. In conclusion, our study provides deeper mechanistic insight into the effect of SYK inhibition in CLL...
  10. doi request reprint Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia
    Maike Buchner
    University Medical Center Freiburg, Department of Hematology and Oncology, Germany
    Cancer Res 69:5424-32. 2009
    ..Combination of SYK inhibitors with fludarabine might be a novel treatment option particularly for CLL patients with poor prognosis and should be further evaluated in clinical trials...
  11. doi request reprint PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4-mediated microenvironmental interactions (PIM1)
    Sarah Decker
    Authors Affiliations Department of Hematology Oncology Centre of Chronic Immunodeficiency, University Medical Centre Freiburg Faculty of Biology BIOSS Centre for Biological Signaling Studies, University of Freiburg, Freiburg, Germany Department of Biomedicine, University Hospital Basel, Basel, Switzerland Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School Department of Cancer Biology, Dana Faber Cancer Institute, Boston, Massachusetts and Department of Hematology, Leiden University Medical Centre, Leiden, The Netherlands
    Mol Cancer Ther 13:1231-45. 2014
    ....
  12. pmc MPN patients harbor recurrent truncating mutations in transcription factor NF-E2
    Jonas S Jutzi
    Department of Hematology Oncology, University Hospital Freiburg, 79106 Freiburg, Germany
    J Exp Med 210:1003-19. 2013
    ..NF-E2 mutant cells acquire a proliferative advantage, witnessed by clonal dominance over WT NF-E2 cells in MPN patients. Our data underscore the role of increased NF-E2 activity in the pathophysiology of MPNs...